Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical ... and are now proceeding with the enrollment process.” Tempus has spent years ...

BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...

New Release of Advarra's Study Collaboration Solution Provides Sponsors and CROs a Single View into the Progress of Site Activation Milestones and IRB Review Status Across Sites Already ...

Amtagvi has the potential to be approved in three new markets in 2025, including the United Kingdom, Canada, and all EU member states. Recently, the i CTC and Iovance's contract manufacturer ...

Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for ...

Q1 2025. Management View. CEO Gerard Michel highlighted the combined Q1 2025 revenue of $19.8 million, with HEPZATO contributing $18 ...

Commercial Channel revenue up 18% Integrity Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good day and welcome to the Delcath Systems’ First Quarter 2025 ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...